Envestnet Asset Management Inc. Has $26.61 Million Stake in Edwards Lifesciences Corporation $EW

Envestnet Asset Management Inc. decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 14.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 340,296 shares of the medical research company’s stock after selling 56,459 shares during the quarter. Envestnet Asset Management Inc. owned about 0.06% of Edwards Lifesciences worth $26,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $27,000. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the second quarter worth approximately $28,000. Costello Asset Management INC bought a new position in shares of Edwards Lifesciences during the first quarter worth approximately $29,000. Finally, Riverview Trust Co increased its holdings in shares of Edwards Lifesciences by 44.5% during the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on EW. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday. UBS Group reaffirmed a “neutral” rating and set a $90.00 target price on shares of Edwards Lifesciences in a report on Monday. Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.7%

Shares of EW stock opened at $83.06 on Tuesday. The stock’s fifty day moving average price is $77.62 and its two-hundred day moving average price is $77.05. The company has a market cap of $48.76 billion, a PE ratio of 11.95, a P/E/G ratio of 3.97 and a beta of 1.05. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.